Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

Abstract Background The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, have been demonstrated in randomized, double-blind, pl...

Full description

Bibliographic Details
Main Authors: Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson-Lomba, Stephen F. Thompson, Michael Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari
Format: Article
Language:English
Published: BMC 2022-04-01
Series:The Journal of Headache and Pain
Subjects:
Fremanezumab
CGRP
Migraine preventive treatment
Real-world effectiveness
Chart review
Online Access:https://doi.org/10.1186/s10194-022-01411-1

Internet

https://doi.org/10.1186/s10194-022-01411-1

Similar Items